Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD Patients
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 204 participants.
Also called NCT04790513
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 204 participants
- Sponsor
- Registry
-
NCT04790513
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT04790513. Randomized; quadruple masking; primary purpose treatment. Start 2021-04-22 (actual); primary completion 2022-09-30 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD Patients
- Acronym
- LIBerate-H2H
- Condition
- Hypercholesterolemia
- Condition
- Cardiovascular Diseases
- Intervention (Biological)
- lerodalcibep
- Intervention (Biological)
- evolocumab
- Intervention (Biological)
- alirocumab
- Lead sponsor
- LIB Therapeutics LLC
Record details
- Record id
cardio:ct-nct04790513- Content hash
44b7842e5ea34aecbb1125607b406009660bb3892979b7b51539b4bcd0d846e3